Thymalfasin
From PeptidePlaza, the free peptide reference · Entry #1100 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Thymalfasin (also known as Thymosin alpha 1, Zadaxin, alpha1-Thymosin, Thymosin alpha1 (human)) is a metabolic research peptide. Thymalfasin, also known as Thymosin alpha 1, is a synthetic peptide that has been investigated for its immunomodulatory properties.
Thymalfasin is a synthetic peptide corresponding to the N-terminal fragment of thymosin alpha 1, a naturally occurring thymic hormone. It is currently in Phase 3 clinical trials for several conditions, including chronic hepatitis C, sepsis, severe acute respiratory syndrome, and colorectal neoplasms. It has also been studied in Phase 2 trials for small cell lung carcinoma, chronic renal insufficiency, and non-small-cell lung carcinoma. Research on thymalfasin has explored its use in neoadjuvant immunochemotherapy for gastric cancer and its effects on perioperative immune function and prognosis in colorectal cancer patients. Reviews have also discussed its applications in immuno-oncology and its role in treating hepatitis B and C.
1 Mechanism of action
Unknown
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Chronic Hepatitis C
- Sepsis
- Severe Acute Respiratory Syndrome
- Colorectal Neoplasms
- Hepatitis C
- Small Cell Lung Carcinoma
- Chronic Renal Insufficiency
- Carcinoma, Non-Small-Cell Lung
3 Chemical and physical properties
| CAS number | 62304-98-7 |
|---|---|
| Molar mass | 3108.3 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
4 Research studies (8)
- Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial
BMC medicine (2026) - A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer
Biotechnology & genetic engineering reviews (2024) · RCT - Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era
International immunopharmacology (2023) - Thymalfasin in the treatment of hepatitis B and C
Annals of the New York Academy of Sciences (2010) · Review - Thymalfasin: an immune system enhancer for the treatment of liver disease
Journal of gastroenterology and hepatology (2004) · Review - A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection
The Journal of infectious diseases (2023) - Identification and determination of structurally related peptide impurities in thymalfasin by liquid chromatography-high-resolution mass spectrometry
Analytical and bioanalytical chemistry (2022) - Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms
Pneumonia (Nathan Qld.) (2023)
5 Safety and risk profile
5.1 Regulatory status
Thymalfasin is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Thymalfasin?
- Thymalfasin, also known as Thymosin alpha 1, is a synthetic peptide. It is a derivative of thymosin alpha 1, a hormone naturally produced by the thymus gland, which plays a role in immune system regulation.
- What is Thymalfasin used for?
- Thymalfasin is being studied for several conditions, including chronic hepatitis C, sepsis, severe acute respiratory syndrome, and colorectal neoplasms. It has also been investigated for small cell lung carcinoma, chronic renal insufficiency, and non-small-cell lung carcinoma.
- What is the regulatory status of Thymalfasin?
- Thymalfasin is currently in Phase 3 clinical trials for several indications, such as chronic hepatitis C, sepsis, severe acute respiratory syndrome, and colorectal neoplasms. It has also reached Phase 2 for other conditions.
- What research has been conducted on Thymalfasin?
- Research on Thymalfasin includes studies on its use in neoadjuvant immunochemotherapy for gastric cancer and its impact on immune function and prognosis in colorectal cancer. Reviews have also examined its broader applications in immuno-oncology and its role in treating liver diseases like hepatitis B and C.
7 References
- Thymalfasin — compound summary PubChem. View source
- Thymalfasin — molecule record ChEMBL. View source
- Thymalfasin — published literature (58 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Thymalfasin.
Also metabolic
Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.
Also metabolic
Ghrelin is a peptide hormone that acts as a ligand for the growth hormone secretagogue receptor (GHSR). It is involved in regulating appetite, metabolism, and growth hormone release.
Also metabolic
Seractide Acetate is a synthetic peptide that acts as a melanocortin receptor 2 agonist.
Also metabolic
Parathyroid Hormone is an 84-residue peptide that acts as a parathyroid hormone receptor agonist. It is FDA approved and marketed as Bestmade Natural Products BM67.
Also metabolic
Octreotide is a somatostatin analog indicated for reducing growth hormone and IGF-1 levels in acromegaly, and for managing severe diarrhea and flushing associated with metastatic carcinoid tumors and VIPomas.
Also metabolic
The GLP-1 that proved the class. A C16 palmitoyl chain gave native GLP-1 a 13-hour half-life instead of two minutes — and produced the first cardiovascular outcome data for the family.